

Ascendiant Capital Markets LLC serves as Financial Advisor on \$25,200,000 Registered Direct for Atossa Therapeutics, Inc.

JUPITER, Florida -- January 8, 2021 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the closing of a \$25,200,000 Registered Direct for Atossa Therapeutics, Inc. (NasdaqCM: ATOS) of Seattle, Washington.

Ascendiant served as a Financial Advisor on the transaction.

The Company intends to use the net proceeds for general corporate purposes, including clinical studies of its products under development. The Company may also use a portion of the net proceeds for the acquisition of businesses, products, technologies or licenses that are complementary to its business, although there are no present commitments or agreements in place.

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. (NasdaqCM: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 561.427.1727 or bwilhite@ascendiant.com.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.